ERBB2 and neoplasm: In comparison to mice with HER2- tumors, 131I-NM-02-treated HER2+ xenografts displayed significantly reduced tumor growth and increased survival times with optimal organ compatibility, hinting at the potential translation of said agent for clinical use [88].